Cyclopharm Ltd has released a press release.
CYC Half Yearly Reports and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cyclopharm
- Announcement of buy-back - Appendix 3C
- CYC Update - R&D Tax Incentive, USFDA, German Litigation
- CANM Endorses Technegas
- Positive USFDA Meeting - Technegas sales expected in 2019
- Cyclopharm 2018 First Half Preliminary Headline Update
Later from Cyclopharm
- CYC Business Update
- Pause in Trading
- Agreement to utilise cyclotron facility assets
- CYC Institutional Placement - Premium To Share Price
- Cyclopharm Company Update
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm